A team of microbiologists, chemists and pharmaceutical specialists at Shandong University, Guangzhou Medical University, ...

A virus originally found in animals, mpox -- which causes the disease of the same name -- is now circulating in humans. Since 2022, it has been the cause of major epidemics spreading outside endemic ...

Compounding pharmacies aren’t the only makers of off-brand versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

While Novo Nordisk (NVO) and Eli Lilly (NYSE:LLY) still rule the weight-loss drug market with their respective GLP-1 medications, competition could soon be heating up as rival products near ...

Tirzepatide, the active ingredient in Eli Lilly's diabetes drug Mounjaro, may be an effective alternative to painful daily treatment for a rare disorder, according to research published Jan. 29 in ...

Ophthalmic complications were observed in patients using semaglutide and tirzepatide, but a causal link was not established. The study included nine patients, with conditions like nonarteritic ...

Human Pilot Study #3: Human Pilot Study #3 (GLP-1-H24-3) was designed to investigate the safety, tolerability, and pharmacokinetics of the injectable drug tirzepatide versus an oral DehydraTECH ...

“Each injection is painful.” In a recent study, researchers explored if diabetes and obesity drug tirzepatide (the active ingredient in Zepbound and Mounjaro) could improve CGL, as it improves ...

39,001 people played the daily Crossword recently. Can you solve it faster than others?39,001 people played the daily Crossword recently. Can you solve it faster than others?

Interneurons have a multipolar structure that allows them to receive multiple signals and then send a unified command to another neuron. In this way, you can think of interneurons as traffic ...

With its offering of tirzepatide (branded as Mounjaro and Zepbound), Eli Lilly and Co. (NYSE: LLY) was another key pharma player in this new type of treatment for diabetes and obesity.